FindTrial
Sign In

Efficacy of Tranexamic acid in Reducing Blood Products and Cost in Degenerative Lumbar Scoliosis (DLS) Patients Undergoing Multi-level Instrumented Fusion Surgery:a Retrospective Study Based on Medical Records

Efficacy of Tranexamic acid in Reducing Blood Products and Cost in Degenerative Lumbar Scoliosis (DLS) Patients Undergoing Multi-level Instrumented Fusion Surgery:a Retrospective Study Based on Medical Records

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2000030948
Enrollment
Unknown
Registered
2020-03-19
Start date
2020-04-01
Completion date
Unknown
Last updated
2020-03-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Degenerative lumbar scoliosis

Interventions

TXA group:TXA
NTXA group:None

Sponsors

The Third Hospital of Beijing University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
40 Years to 82 Years

Inclusion criteria

Inclusion criteria: DLS patients underwent posterior multilevel spinal fusion (>=5 vertebraes) from April 2014 to June 2018

Exclusion criteria

Exclusion criteria: 1. Patients with chronic renal failure; 2. With cirrhosis of the liver; 3. With chronic heart failure; 4. Patients allergic to TXA; 5. With histories of thromboembolic disease, bleeding disorders, hypercoagulation status, disseminated intravascular coagulation; 6. Those underwent revision surgery; 7. Those receiving antiplatelet and anticoagulant drugs; 8. Those with dural tear during the operation.

Design outcomes

Primary

MeasureTime frame
blood loss;—

Secondary

MeasureTime frame
transfusion;—

Countries

China

Contacts

Public ContactYan Zeng

The Third Hospital of Beijing University

zyanby@163.com+86 18518590006

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026